X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $11.25.
Separately, Weiss Ratings upgraded X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, November 3rd.
View Our Latest Analysis on X4 Pharmaceuticals
Insider Buying and Selling at X4 Pharmaceuticals
In other news, Chairman Adam Craig sold 47,436 shares of X4 Pharmaceuticals stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $4.44, for a total value of $210,615.84. Following the transaction, the chairman owned 328,651 shares of the company’s stock, valued at $1,459,210.44. This trade represents a 12.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, President John Volpone sold 24,576 shares of the business’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total transaction of $109,117.44. Following the completion of the sale, the president owned 265,305 shares of the company’s stock, valued at $1,177,954.20. The trade was a 8.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 83,779 shares of company stock worth $353,387 over the last 90 days. Insiders own 1.13% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of XFOR. Perceptive Advisors LLC boosted its stake in X4 Pharmaceuticals by 6.7% during the 1st quarter. Perceptive Advisors LLC now owns 6,737,648 shares of the company’s stock valued at $27,826,000 after purchasing an additional 423,196 shares during the period. Bank of New York Mellon Corp acquired a new stake in X4 Pharmaceuticals in the 2nd quarter valued at approximately $917,000. Bank of America Corp DE increased its position in X4 Pharmaceuticals by 321.3% in the 1st quarter. Bank of America Corp DE now owns 150,676 shares of the company’s stock worth $622,000 after buying an additional 114,915 shares during the period. Russell Investments Group Ltd. increased its position in X4 Pharmaceuticals by 2,871.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 213,258 shares of the company’s stock worth $618,000 after buying an additional 206,080 shares during the period. Finally, Alps Advisors Inc. lifted its holdings in shares of X4 Pharmaceuticals by 36.2% during the third quarter. Alps Advisors Inc. now owns 130,424 shares of the company’s stock worth $378,000 after buying an additional 34,698 shares during the last quarter. Institutional investors own 72.03% of the company’s stock.
X4 Pharmaceuticals Price Performance
Shares of NASDAQ:XFOR opened at $3.18 on Monday. X4 Pharmaceuticals has a fifty-two week low of $2.43 and a fifty-two week high of $4.83. The business has a 50-day moving average of $3.23 and a two-hundred day moving average of $3.78. The stock has a market capitalization of $315.30 million, a P/E ratio of -4.75 and a beta of 0.47. The company has a debt-to-equity ratio of 0.55, a current ratio of 13.22 and a quick ratio of 12.86.
X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01. The business had revenue of $2.88 million for the quarter, compared to analyst estimates of $2.78 million. X4 Pharmaceuticals had a negative return on equity of 49.62% and a negative net margin of 474.74%. On average, equities research analysts predict that X4 Pharmaceuticals will post -0.68 EPS for the current fiscal year.
X4 Pharmaceuticals Company Profile
X4 Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing therapies for rare diseases caused by disorders of the immune system. The company’s research centers on the CXCR4 pathway, which plays a role in the movement and function of immune cells.
X4’s lead product, XOLREMDI (mavorixafor), is an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration for use in patients aged 12 and older with WHIM syndrome, a rare primary immunodeficiency disorder.
Featured Stories
- Five stocks we like better than X4 Pharmaceuticals
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
